SCHEMBL22070486

SCHEMBL22070486

CCOC(=O)C(C)(C)Oc1cccc(C/C=C/C(=O)OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.55
PPARG P37231 3/20 0.55
FBP1 P09467 6/20 0.47
F13A1 P00488 1/20 0.43
TGM2 P21980 1/20 0.43
TGM1 P22735 1/20 0.43
HCAR2 Q8TDS4 1/20 0.43
ABCB11 O95342 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
HTR2A P28223 1/20 0.43
PMP22 Q01453 1/20 0.43
LMNA P02545 1/20 0.41
AKR1B10 O60218 2/20 0.41
AKR1B1 P15121 2/20 0.41
TTR P02766 1/20 0.41
GRM2 Q14416 1/20 0.40
CA12 O43570 1/20 0.39
CA4 P22748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21188241 0.81 PPARA (0.67) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL6081371 0.81 PPARA (0.61) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL13141027 0.78 PPARA (0.66) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL6081046 0.77 PPARA (0.67) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL6093013 0.76 PPARA (0.70) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL14291406 0.75 PPARA (0.69) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL6091395 0.75 PPARA (0.69) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL1549446 0.75 PPARA (0.69) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL197882 0.75 PPARA (0.64) PPARAPPARGFBP1ABCB11CYP1A2
SCHEMBL2824491 0.74 PPARA (0.71) PPARAPPARGFBP1ABCB11CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 EP disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 PPARA 1387/4885PPARG 1267/4885FBP1 1261/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 PPARA 1387/4885PPARG 1267/4885FBP1 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.